Quick Answer
Xtant Medical Holdings, Inc. reported R&D Expense of $2.10 million for fiscal year 2025.
Xtant Medical Holdings, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.10M | -11.9% |
| 2024 | $2.38M | +78.5% |
| 2023 | $1.34M | +46.0% |
| 2022 | $915.0K | +5.2% |
| 2021 | $870.0K | +32.4% |
| 2020 | $657.0K | -29.5% |
| 2019 | $932.0K | -45.2% |
| 2018 | $1.70M | -30.3% |
| 2017 | $2.44M | -28.4% |
| 2016 | $3.41M | +33.9% |
| 2015 | $2.55M | +76.5% |
| 2014 | $1.44M | +152.1% |
| 2013 | $572.4K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $634.0K | -9.6% | +12.0% |
| June 30, 2025 | $566.0K | -11.0% | +27.8% |
| March 31, 2025 | $443.0K | -15.9% | -36.8% |
| September 30, 2024 | $701.0K | +43.1% | +10.2% |
| June 30, 2024 | $636.0K | +253.3% | +20.7% |
| March 31, 2024 | $527.0K | +202.9% | +7.6% |
| September 30, 2023 | $490.0K | +114.0% | +172.2% |
| June 30, 2023 | $180.0K | -25.3% | +3.4% |
- Xtant Medical Holdings, Inc. showed a decrease of -11.9% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, Xtant Medical Holdings, Inc.’s r&d expense has grown by 267.3% (from $572.4 thousand to $2.10 million).
- The most recent figure is from Xtant Medical Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: